top of page
  • HS Bio

HS Bio enters collaborative research and development agreement with UM’s TIDREC

Updated: Apr 18, 2022

Hong Seng Consolidated Bhd’s healthcare arm, HS Bio Sdn Bhd, has entered into a collaborative research and development (R&D) agreement with Universiti Malaysia’s Tropical Infectious Diseases Research and Education Centre (TIDREC).

The R&D agreement was done through HS Bio’s wholly-subsidiary, NeoGenix Laboratoire Sdn Bhd.

HS Bio director and NeoGenix Lab Group managing director Dr. Kuan Chee Sian said the company and TIDREC would work together in a epidemiologic bio-surveillance project to determine the etiologies of acute febrile respiratory illnesses in Malaysia.

He said the research project is aimed at studying the set of causes and the pathogens of the acute febrile illnesses with rapid onset of fever and symptoms such as headache, chills or muscle and joint pains which are common in the tropics and sub-tropics countries like Malaysia and the region.

“Hence, we are committed to doing our best to live up to the trust given to us by adhering to world-class quality and highest ethical standards in our services,” he said in a statement today.

7 views0 comments


Commenting has been turned off.
Post: Blog2_Post
bottom of page